Recurrent large-scale somatic copy number alterations (SCNAs), and somatic point mutations can be analysed to stratify patients with chronic lymphocytic leukaemia (CLL) into distinct prognostic groups. To investigate the relationship between SCNAs and somatic mutations, we performed whole-exome sequencing and single nucleotide polymorphism microarray analyses on 98 CLL patients from 40 families with a high burden of CLL. Overall, 69 somatic mutations in 29 CLL driver genes were detected among 45 subjects (46%), with the most frequently mutated genes being TP53 (8Á2%), NOTCH1 (8Á2%) and ATM (5Á1%). Additionally, 142 SCNAs from 54 subjects (57%) were detected, including losses of chromosome 13q14 (28Á9%), 11q (5Á6%), 17p (2Á1%), and gain of chromosome 12 (4Á2%). We found that patients having both an adverse point mutation in a CLL driver gene and an unfavourable SCNA tended to have poorer survival (Hazard ratio [HR] = 3Á17, 95% confidence interval [CI] = 0Á97-10Á35; P = 0Á056) than patients having either a point mutation (HR = 1Á34, 95%CI = 0Á66-2Á71; P = 0Á42) or SCNAs (HR = 2Á65, 95%CI = 0Á77-9Á13; P = 0Á12). TP53 mutation carriers were associated with the poorest overall survival (HR = 4Á39, 95%CI = 1Á28-15Á04; P = 0Á018). Our study suggests that combining SCNA and mutational data could contribute to predicting outcome in familial CLL.
Summary
Recurrent large-scale somatic copy number alterations (SCNAs), and somatic point mutations can be analysed to stratify patients with chronic lymphocytic leukaemia (CLL) into distinct prognostic groups. To investigate the relationship between SCNAs and somatic mutations, we performed whole-exome sequencing and single nucleotide polymorphism microarray analyses on 98 CLL patients from 40 families with a high burden of CLL. Overall, 69 somatic mutations in 29 CLL driver genes were detected among 45 subjects (46%), with the most frequently mutated genes being TP53 (8Á2%), NOTCH1 (8Á2%) and ATM (5Á1%). Additionally, 142 SCNAs from 54 subjects (57%) were detected, including losses of chromosome 13q14 (28Á9%), 11q (5Á6%), 17p (2Á1%), and gain of chromosome 12 (4Á2%). We found that patients having both an adverse point mutation in a CLL driver gene and an unfavourable SCNA tended to have poorer survival (Hazard ratio [HR] = 3Á17, 95% confidence interval [CI] = 0Á97-10Á35; P = 0Á056) than patients having either a point mutation (HR = 1Á34, 95%CI = 0Á66-2Á71; P = 0Á42) or SCNAs (HR = 2Á65, 95%CI = 0Á77-9Á13; P = 0Á12). TP53 mutation carriers were associated with the poorest overall survival (HR = 4Á39, 95%CI = 1Á28-15Á04; P = 0Á018). Our study suggests that combining SCNA and mutational data could contribute to predicting outcome in familial CLL.
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Chronic lymphocytic leukaemia (CLL) is the most common B cell leukaemia in the United States. In 2017, the American Cancer Society estimated that 21 110 individuals would be diagnosed with CLL (American Cancer Society 2017). Incidence rates increase with age, and are nearly twice as high in males as females (Howlander et al, 2015) . CLL has a variable clinical course, ranging from patients experiencing long indolent periods without treatment to others developing aggressive disease. Traditional cytogenetic studies (such as fluorescence in situ hybridization, FISH) and, more recently, array comparative genomic hybridization (CGH) and single nucleotide polymorphism (SNP) microarray analyses have been used to define a set of recurrent large somatic copy number alterations (SCNAs) characteristic of CLL, such as deletions of 11q22.3 (del(11q)), 13q14 (del(13q)) and 17p13 (del(17p)), as well as trisomy 12 (dup(12)) and other rare events (Dohner et al, 2000; Pfeifer et al, 2007; Berkova et al, 2008; Gunn et al, 2008; Edelmann et al, 2012; JimenezZepeda et al, 2013) . More than 80% of patients present with one or more SCNAs at the time of diagnosis or over the course of disease (Hallek et al, 2008) . SCNAs have diagnostic and prognostic value, but the molecular basis for their role in CLL and the full implications for therapy require further study. The most frequent SCNA is del(13q) (~50% of CLL cases) (Ouillette et al, 2011) . There is substantial heterogeneity in the size and characteristics of del(13q) (Pfeifer et al, 2007; Ouillette et al, 2008; Mosca et al, 2010; Parker et al, 2011; Zhao et al, 2016) , though common to all is a minimally-deleted region (MDR) that contains the non-proteincoding Deleted in Lymphocytic Leukaemia 1 and 2 genes (DLEU1 and DLEU2). A number of studies have investigated the prognostic significance of del(13q) (Dal Bo et al, 2011; Ouillette et al, 2011) , and suggest that patients with deletions of the MDR exclusive of the nearby RB1 gene have a more favorable outcome (Dohner et al, 2000) , particularly if it is the sole aberration present, compared to those with deletions that include RB1 (Dal Bo et al, 2011; Ouillette et al, 2011) . However, more recent work suggests that, for CLL, the presence of these deletions, regardless of size, are largely favourable (Yi et al, 2017) . It is also notable that the del(13q) observed in CLL is also observed in healthy adults as a detectible mosaic chromosomal abnormality -namely the presence of a subset of circulating lymphocytes with this large structural mosaic event (Machiela et al, 2016) . dup(12)has been reported in 10-20% of CLL cases (Stilgenbauer et al, 2002) and confers an intermediate prognosis (Matutes et al, 1996; Dohner et al, 2000) . del(17p) and del (11q), which contain the tumour protein 53 gene (TP53) and the ataxia telangiectasia mutated gene (ATM), respectively, are associated with disease progression and poorer survival (Dohner et al, 1995 (Dohner et al, , 2000 Zenz et al, 2008; Pospisilova et al, 2012) . Other uncommon chromosomal abnormalities have been reported (Schwaenen et al, 2004; Chapiro et al, 2010) .
Tumour sequencing studies have revealed recurrent somatic single-nucleotide point mutations in CLL patients and a recent review singled out 52 genes with recurrent mutations in lymphomas, which includes 23 recurrently mutated in CLL (Gruber & Wu, 2014) . The three most commonly mutated genes are SF3B1, NOTCH1, and TP53 (Schnaiter et al, 2013) . Puente et al (2015) conducted wholegenome sequencing of 452 CLL cases and 54 patients with monoclonal B cell lymphocytosis (MBL) and have extended the number of driver mutations. Similar to SCNAs in sporadic CLL, somatic point mutations can be associated with prognosis. Most mutations are associated with poor prognosis, though mutations in MYD88, CHD2, and KLHL6 are favourable (Puente et al, 2015) .
Because both SNCAs and somatic point mutations have been associated with prognosis, we investigated the relationship between somatic point mutation and SCNA status in 98 CLL subjects from 40 CLL-prone families. We analysed possible mutations in the 52 recurrent putative driver genes for the lymphomas cited above (Gruber & Wu, 2014) . Additionally, we determined somatic copy number alteration status and frequencies of four common CLL-associated cytogenetic aberrations: del(13q), del(11q), del(17p), and dup(12).
Methods

Patients
CLL families included in this study are participants in an institutional review board (IRB) approved study at the United States National Cancer Institute (protocol NCI 02-C-0210) and were accrued through healthcare professionals or self-referral (Goldin et al, 2010a) . Clinical, morphological and genetic features of CLL in these families have been previously described (Ishibe et al, 2001; Goldin et al, 2010b) . The present study includes analyses of 98 CLL patients from 40 CLL-prone families.
Whole exome sequencing
Whole-exome sequencing (WES) for the CLL families was performed at the Cancer Genomics Research Laboratory, National Cancer Institute (CGR, NCI), as previously described (Shi et al, 2014) . Briefly, genomic DNA was extracted by standard methods from blood. The SeqCAP EZ Human Exome Library v3.0 (Roche NimbleGen, Madison, WI, USA) was used with 1Á1 lg of DNA for exome sequence capture. The captured DNA was subjected to paired-end sequencing utilizing the Illumina HiSeq2000 sequencer for 2 9 100-bp sequencing of paired-ends (Illumina, San Diego, CA, USA). Exome sequencing was performed to a sufficient depth to achieve a minimum coverage of 15 reads in at least 80% of the coding sequence from the University of California, Santa Cruz (UCSC) hg19 transcripts database (http://ge nome.ucsc.edu/cgi-bin/hgGateway).
Sequence alignment
Details of the bioinformatics pipeline for variant alignment and calling used in this study have been previously published (Shi et al, 2014) . Briefly, WES reads were trimmed using the Trimmomatic program (Bolger et al, 2014) , which reported the longest high-quality stretch of each read. Only read pairs with both ends ≥36 bp were used. Reads were aligned to the hg19 reference genome using the Novoalign software version v3.00.05 (http://www.novocraft.com). Duplicate reads based on paired ends aligning to the same start locations due to either optical or polymerase chain reaction (PCR) artifacts were removed from further analysis using the MarkDuplicated module of the Picard software v1.126 (http://pica rd.sourceforge.net/). Additionally, two ends of each pair had to map to the reference in complementary directions and reflect the expected fragment length (300 AE 100 bp). A local realignment around sites of insertion and deletion was performed using the RealignerTargetCreator and IndelRealigner modules from the Genome Analysis Toolkit (GATKv3.1) (DePristo et al, 2011) .
Somatic mutation analysis
The MuTect1 software package (http://archive.broadinsti tute.org/cancer/cga/mutect) was used to identify candidate somatic point mutations in whole-exome sequence data using default parameter settings, which required a minimum of 14 reads covering a site in the tumor and 8 in the normal for declaring a site adequately covered for mutation calling . Indelocator software (https:// www.broadinstitute.org/cancer/cga/indelocator) was used to identify short somatic insertions and deletions. Each tumour sample was paired with an unmatched normal to filter out any variants existing in both tumour and unmatched normal samples. All point mutations were further subjected to filtering against a large panel of 476 control samples from a study of germline cutaneous malignant melanoma (CMM) to further remove nonspecific variants existing in at least two samples in the control panel. The non-synonymous variants generated from MuTect1 and Indelocator were further filtered out if they were shared by more than one family member or shared by any individuals within our Division of Cancer Epidemiology and Genetics Exome set. Some of the sequence data were also manually checked for possible misalignment using BLAT search (http://genome.ucsc.edu/cgi-bin/hgBlat) and IGV (http://sof tware.broadinstitute.org/software/igv/). All candidate somatic mutations were subjected to deep target sequence validation on all 98 subjects using the Ion AmpliSeq Panel (see below "Targeted sequencing -AmpliSeq & Ion Proton Sequencer" and "Ion variant calling" in the Methods section for details). Only validated mutations were used for any downstream analysis.
Targeted sequencing -AmpliSeq & ion proton sequencer
A targeted, multiplex PCR primer panel was designed using the custom Ion AmpliSeq Designer v5.4.1 (Life Technologies, Carlsbad, CA, USA). The primer panel covered 42Á21 kb of target regions that included potential mutations identified from MuTect1 software. Additionally, we also included two reported highly recurrent mutations in the NOTCH1 gene: (1) chr9: 139390648 (2) chr9: 139390152 (non-coding region); and mutations in the TP53, ATM, MYD88 and POT1 genes (coding region only). Design coverage of the intended targets was 98Á9%. Average amplicon size of the 228 amplicons in the design was 242 bp. Sample DNA (30 ng) was amplified using this custom AmpliSeq primer pool, and barcoded libraries were prepared for each sample following the manufacturer's Ion AmpliSeq Library Preparation protocol (Life Technologies, Carlsbad, CA, USA). After library preparation, up to 96 libraries were pooled, templated and sequenced on the Proton Sequencer using the Ion P1 200 bp Kit and the P1 chip per manufacturer's instructions (Life Technologies, Carlsbad, CA, USA).
Ion Torrent variant calling
Sequence data were processed using standard Ion Torrent Suite Software (Thermo Fisher Scientific) run on the Ion Torrent server. Raw signal data were analysed using the Torrent Suite software version 5.0.7. The data processing pipeline includes signal processing, base calling, quality score assignment, adapter trimming, PCR duplicate removal, read alignment to hg19, coverage analysis and variant calling. For the variant calling, we used the Torrent Variant Caller (TVC) algorithm with the somatic parameter setting, i.e., the coverage depth was ≥6 and the variant allele frequency was ≥2%.
Somatic copy number alteration (SCNA) detection
Genome-wide SNP genotyping (HumanOmniExpress12v1_A, Illumina) was independently conducted on 95 of the 98 individuals with WES data. Log R ratio (LRR) and B allele frequency (BAF) were used to assess SCNAs derived from SNP array intensity data as previously described (Peiffer et al, 2006) . The LRR and BAF values from qualified assays (completion rate ≥ 90%) were re-normalized (Diskin et al, 2008; Staaf et al, 2008) and then analysed using previously published custom software pipelines (Jacobs et al, 2012 ) that detect SCNAs with a minimum of 200 probes per segment to minimize false discovery. All potential events were plotted and visualized, and false positive calls were excluded from the analysis based on manual review of each plot. The proportion of cancer cells were calculated using a previouslydescribed method (Jacobs et al, 2012) .
To identify all chromosome del(13q) events, a t-test was used to examine deviations of the expected from the actual LRR and BAF for the region between 49 139 793 and 50 269 706 bp (Genetics Reference Consortium Ch36 build, GRCh36;
https://genome.ucsc.edu/cgi-bin/hgGateway?db= hg18). An unequal variance t-test was applied to each sample to compare the mean LRR value and BAF values for the tested regions to those on chromosome 1 (reference) to determine if there is a difference. Results from t-tests were plotted and manually reviewed to confirm the del(13q) focal deletion.
Survival analysis
Kaplan-Meier survival plots and Cox proportional-hazard models were generated in R using the Survival package (https://cran.r-project.org/web/packages/survival/survival.pdf). Using age as the time-scale, the start year is the later date of either year of cancer diagnosis or year of DNA collection, and the end year is the year of death or censorship. In this study, the age at cancer diagnosis was typically before the age at DNA collection. For overall survival analysis, the event indicator equalled one for those who died during the study follow-up and zero for those who were alive at the date of last follow-up. Due to the limited sample size, we combined all patients with del(13q) as the only copy number variation (both type I and extended) into a group we designated as single del(13q). The following covariate terms were defined for each individual: (i) age (a continuous measure of age at DNA collection); (ii) treatment (categorical variable with two levels: treated, untreated (reference group)); (iii) Rai stage (categorical variable with three levels: stage 0 (reference group), stage I and II, stage III and IV). (iv) mutation (categorical variable with three levels: protective mutation (detected in MYD88, CHD2 and KLHL6), no mutation, and adverse mutation (all others). (v) SCNA (categorical variable with 3 levels: single del(13q), no SCNA, and adverse SCNA (all others). (vi) mutation and SCNA (categorical variable with 3 levels: adverse mutation and adverse SCNA, single del (13q), others).
Other analyses
The odds ratios and the 95% Confidence Interval (CI) unadjusted analysis of count data and frequencies were calculated using fisher.test in the R software package. This program calculates the Fisher's Exact test statistic and generates an odds ratio and 95% confidence intervals using the conditional maximum likelihood estimates (https://stat.ethz.ch/R-manua l/R-devel/library/stats/html/fisher.test.html). The GLU software package (https://github.com/snewhouse/glu-genetics) was used to estimate completion rate and other quality control parameters for each subject for the SNP microarray data.
Results
Somatic point mutations
A total of 98 CLL subjects from 40 CLL families with two to five affected family members were subjected WES. The average sequencing depth across samples was~809. Somatic mutation detection was performed for 52 genes reported to harbour recurrent driver mutations in mature B cell nonHodgkin lymphomas (Gruber & Wu, 2014) . Overall, 72 nonsynonymous somatic mutations were detected, 59 of which (80%) were validated by deep targeted sequencing (average depth of 40239 +/À966). During the validation process, 10 new mutations were discovered that were not detected by WES (8 from NOTCH1). Therefore, 69 somatic mutations from 29 genes were validated in 45 subjects (46%) and 18 subjects (38Á4%) had multiple mutations (two to three mutations). These mutations were observed in 14 of the 23 CLL genes reported by Gruber and Wu (2014) , and all were nonsynonymous except two in an intron of NOTCH1. The most frequently mutated genes were TP53 (8Á2%), NOTCH1 (8Á2%) and ATM (5Á1%) (Table SIA and SIB and Figure S1 ). Three genes harboured previously described recurrent point mutations: two mutations in NOTCH1, MYD88 
SCNAs
Ninety-five of 98 CLL patients had available SNP microarray data (Illumina Infinium OmniExpress BeadArray). Overall, 142 detectable somatic chromosomal alterations from 54 subjects (57%) were detected, including the four most common CLL-associated cytogenetic aberrations: del(13q), del(11q), del(17p), and dup(12) (Table SIIA-SIIB). del(13q) was observed in 38 of the 98 subjects (40%) with the focal deletion region, 13q14.3 containing miR15a and miR16-1 (type I   Fig 1. The circos plot of detectable somatic copy number aberrations (SCNAs) and their genomic locations (build36) from 95 subjects with chronic lymphocytic leukaemia. Green region is copy-gain events; blue region is copyneutral loss of heterozygosity; red region is copy-loss events. deletion), observed in seventeen subjects (18%). The proportion of cancer cells ranged from 23% to 100%. The larger deletion region involving the above plus the tumour suppressor, RB1 residing on 13q14.2 and known as a type II deletion (Parker et al, 2011) was observed in 21 subjects (22%), with the proportion of cancer cells ranging from 20% to 100%. Twenty-two subjects had del(13q) as the only SCNA event detected (23%). dup(12) was found in six subjects (6Á3%), with the proportion of cancer cells ranging from 24% to 89%; eight del(11q) from six subjects (6Á3%), with proportion of cancer cells ranging from 51% to 93%; finally, three del(17p) from three subjects (3Á2%), with proportion of cancer cells ranging from 51% to 91% (Table SIIB, Fig 1) .
Association and survival analyses
To evaluate the impact of mutations and chromosomal abnormalities on survival, we performed analyses of somatic point mutations, SCNAs, or a combination of both. Because point mutations and SCNAs can be categorized with respect to CLL prognosis, we grouped somatic point mutation status into three mutation groups: protective (mutation in MYD88, CHD2 or KLHL6), no mutation, and adverse (mutation in any other candidate gene). Similarly, we grouped SCNA status into three groups. The first group consisted of single del (13q), where del(13q) is the only SCNA and probably protective. No significant differences were observed between single type I and single type II del(13q), so these were combined for subsequent analyses. The other two groups we considered were no SCNA, and adverse SCNA (SCNA excluding single del(13q)). We examined whether having somatic point mutations or SCNAs or having both have an impact on overall survival. The presence of any somatic point mutation (with or without a co-existing SCNA) is associated with shorter overall survival in Kaplan-Meier survival curves (Fig 2A) though not statistically significant in multivariate-adjusted Cox proportional-hazard models after adjusting for age at DNA collection, gender, treatment, SCNA status, and Rai stage (Hazard ratio [HR] = 1Á34, 95% CI = 0Á66-2Á71; P = 0Á42). Subjects having a somatic mutation in CHD2, MYD88 or KLHL6, had a similar hazard ratio to those without these mutations (HR = 1Á03, 95% CI = 0Á29-3Á68; P = 0Á96) ( Table I) . Eight subjects had mutations in TP53, one of the two most frequently mutated genes (8Á16%) in our study. The presence of a TP53 mutation was significantly associated with shorter overall survival; subjects who had a mutation in TP53 were over four-fold more likely to experience death than those without a TP53 mutation (HR = 4Á39, 95% CI = 1Á28-15Á04; P = 0Á020) (Fig 2B and Table II) .
The presence of any detectable SCNA (with or without a co-existing point mutation) predicted shorter overall survival in a Kaplan-Meier plot (Fig 2C) , though this was not statistically significant after multivariate adjustment (HR = 2Á65, 95% CI = 0Á77-9Á13; P = 0Á12) (Fig 2C, Table I ). However, CLL patients who had at least one of the three driver SCNA events (dup(12), del(11q), del(17p)) had significantly shorter overall survival than those with single del(13q) (HR = 4Á41, 95% CI = 1Á36-12Á48; P = 0Á01) (Fig 2D, Table III ). In total, 11 of 14 cases with at least one of these three driver SCNAs had somatic mutations and none were protective mutations.
We also examined whether the presence of both point mutations and detectable SCNAs were associated with clinical outcome (Fig 2E) . A Fisher's Exact test showed that there was a significant association between having a somatic point mutation and an SCNA (OR = 3Á89, 95% CI = 1Á47-10Á71, P = 0Á003); subjects with deleterious somatic point mutations are more likely to also have an adverse SCNA. Co-occurrence of both types of events was marginally significantly associated with shorter overall survival compared to single del(13q) (HR = 3Á17, 95% CI = 0Á97-10Á35; P = 0Á056) (Table IV) , which, in turn, might be worse than the presence of a deleterious point mutation (HR = 1Á34 and P = 0Á42) (Table I) or an SCNA (HR = 2Á65 and P = 0Á12) (Table I) alone.
Discussion
A hallmark of CLL is the presence of recurrent large-scale SCNAs and putative driver gene mutations, both of which could have prognostic importance. To better understand the relationships among SCNAs and somatic point mutations, Analyses were adjusted for age DNA collection, gender (ref= female), treatment, Rai stage. The mutation has three levels: subjects with adverse mutations (exclude subjects with mutations on MYD88, CHD2 or KLHL6 genes); protective mutations (subjects with mutations on MYD88, CHD2 or KLHL6 genes; ref); and no mutation. The SCNA variable has three levels: single del(13q) (ref), no SCNA, adverse SCNA (all others). Table II . Survival analysis summary for TP53 somatic mutation overall survival.
Analyses were adjusted for age at DNA collection, gender (ref= female), treatment, Rai stage. Table III . Survival analysis summary for at least one of the 3 driver SCNA events (del(11q), dup(12),del(17p)) overall survival.
Analyses were adjusted for age at DNA collection, gender (ref= female), treatment, Rai stage. The SCNA variable has three levels: single del(13q) (ref), SCNA on one of the three event types (del (11q), del(17p), dup (12)), Others. we performed WES and SNP microarray analyses on 98 individuals with CLL from 40 CLL-prone families. WES data were used to detect somatic point mutations in 52 genes reported as having recurrent putative driver alterations in mature B-cell non-Hodgkin lymphomas (which include CLL), with SCNA analyses performed using SNP microarray data on the same patients. We performed survival analyses in familial cases of CLL, specifically examining somatic mutation and SCNA. Among those with somatic mutations, subjects with mutations in TP53 have poorer survival, as estimated in our familial study with a HR as high as 4Á4. The median survival time is 3Á41 years for those with a TP53 mutation compared to 8Á96 years without a mutation, suggesting that TP53 mutation status has an adverse prognostic implication for familial CLL (Pospisilova et al, 2012) . Among seven subjects carrying TP53 mutations who also had SNP array data, the mean survival time is 13 years for two subjects who carried both TP53 mutations as well as the single chromosome del (13q), compared to 2Á70 years for five subjects without single del(13q). When adjusting for del(13q) in the model, the HR for TP53 mutation increased (HR = 4Á72, P = 0Á01), consistent with a single del(13q) conferring a better prognosis (data not shown). This also suggests that both driver somatic mutations and SCNAs together could contribute independent prognostic information. Landau et al (2013) found TP53 mutations were detected preferentially in sub-clonal populations, which usually corresponds to later events in CLL evolution. This suggests that the presence of a minor clone is associated with poor prognosis or an advanced clinical course. Although mutations in TP53 are reported in both IGHV mutated and IGHV unmutated CLLs (Puente et al, 2015) , in accord with earlier work, our results suggest that TP53 mutation status has independent adverse prognostic implications. The mutation frequencies observed in our familial CLL sample are similar to those in the literature, with the exception of SF3B1 which is lower (2%) than other samples. This may reflect more favourable prognostic features in our sample, a less prominent role for the mutation in familial CLL, or chance (Gunnarsson et al, 2013; Landau et al, 2013; Barrio et al, 2017) .
Although our numbers are small, we find suggestive evidence of associations between specific somatic mutations and SCNAs on the same chromosome in familial CLL. The three subjects with 17p loss had mutations in TP53 and two out of five subjects with ATM mutations also had loss of 11q (Fig 3) , all of which have been associated with poor prognosis (Wang et al, 2011) . Among six subjects with dup(12), two also carried mutations of the KRAS oncogene (Fig 3) , which is located on chromosome 12 and is associated with poor prognosis. Except for two individuals, whose only detectable SCNA was single del(13q), we detected multiple chromosomal aberrations in all other TP53 mutation carriers. The finding of co-occurrence between mutated genes and chromosomal aberrations, such as TP53 and del(17p) is concordant with other findings (Landau et al, 2015) .
We hypothesized that a subject with both an adverse point mutation and SCNAs would have worse overall survival than either one alone. Our findings indicate that familial CLL patients who have both adverse mutation(s) and SCNA(s) have poorer overall survival (HR = 3Á17 and P = 0Á056) (Table IV) than those with a point mutation (HR = 1Á34 and P = 0Á42) or SCNAs (HR = 2Á65 and P = 0Á12) alone (Table I) , but future studies with larger samples will be required to support this observation. Selected chromosomal copy number aberrations and mutation status from 95 chronic lymphocytic leukaemia (CLL) patients with both sequence and single nucleotide polymorphism (SNP) array data. Each rectangle represents a CLL subject. SCNA represents the somatic copy number aberration variable with 3 levels: single del(13q), no SCNA, and adverse SCNA. Green colour represents subjects that have single del (13q) (SCNA) or del(13q) or mutation for at least one of the three protective mutation genes CHD2/KLHL6/MYD88. Red colour represents events excluding single del(13q) (SCNA) or having dup(12) or del(11q) or del(17p) or mutation in TP53/ATM/KRAS genes or death (Death). Grey colour represents no events or no mutation or alive (Death).
In summary, we conducted a study using a well-characterized group of familial CLL patients on whom demographic and clinical data were available; somatic mutation and copy number analysis were performed. Our analysis of familial CLL indicated that there could be prognostic value in assessing specific mutations (e.g., TP53 mutations) and chromosome findings (del(13q)). Study size and technical factors (i.e., whole blood-based studies may contain a low proportion of tumour cells influencing the ability to detect mutations and SCNA) are limitations of our study. Accordingly, testing both single nucleotide mutation and SCNAs could improve prognostic inference if subsequent studies provide supportive evidence. Our study was conducted in cases with a well-characterized family history of CLL. Familial and sporadic cases are quite similar in terms of morphology, clinical features, and inherited gene alterations (Goldin et al, 2010b) , but some differences are reported (Slager et al, 2011) , so findings may not completely generalize to sporadic CLL, indicating the need for further studies.
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